Navigation Links
Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for Asthma or Allergies without Trying First-Line Medications End Up Staying on the Medication
Date:4/27/2011

ST. PAUL, Minn., April 27, 2011 /PRNewswire/ -- Patients with asthma or allergic rhinitis (nasal allergies), initially prescribed montelukast (Singulair®) instead of typical first-line therapy have low rates of persistence on montelukast and may ultimately discontinue therapy altogether, according to a new study presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn. The study will be presented by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management.

Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis. Typical first-line therapies are inhaled corticosteroids for asthma and nasal steroids for allergic rhinitis. The inhaled steroids act locally by concentrating their effects directly within the breathing passages, with very few side effects outside of the lungs or sinuses.

For the study, researchers identified 907 individuals with asthma who filled a claim for newly initiated montelukast therapy in the fourth quarter of 2009. An additional 373 people with allergic rhinitis or allergies who initiated montelukast therapy during the same time period were also identified. Patients were followed for 120 days after their first claim was filled to assess whether they continued to take montelukast after 30, 60, 90 and 120 days.

At 120 days after initiating montelukast therapy, 30.9 percent of asthma patients still had a supply of this medication. A similar poor persistence on montelukast treatment at 120 days was noted in patients with allergic rhinitis. In addition, at 120 days after montelukast was initiated, the vast majority of asthma and allergic rhinitis patients were lacking any therapy (62.6 and 64.9 percent, respectively).

"Continued drug treatment is essential for managing asthma," said
'/>"/>

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. One-Third of Antimalarial Medicines Sampled in Three African Nations Found to Be Substandard in Large-Scale USP-WHO Study
2. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Lightlake Therapeutics Inc. ("Lightlake") ... based on its expertise in opioid antagonists, announced ... from a prominent international research and development foundation. ... promoting innovative research-based initiatives, including those addressing health ... for the delivery of naloxone that could widely ...
(Date:7/30/2014)...  Hospira, Inc. (NYSE: HSP ), ... infusion technologies, today reported results for the second ... the quarter were $1.1 billion and adjusted* diluted ... specified items as described later in this press ... Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2014 ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
(Date:7/30/2014)... 2014 Nationally recognized leader in nursing ... since September 2013 has served as president of the ... dean of the College of Nursing at University of ... leadership of the NLN, as the nation's premier voice ... nursing and research institutions in the country. , ...
(Date:7/30/2014)... 2014 Within weeks freshman will begin to pour ... hopes this will be a time of growth and the start ... pause; it may not be as easy as it looks. Some ... switch their major at least once and many will switch two ... the costs are exacerbated when switching in the later years of ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Throughout the ... patients with free oral cancer screenings. Using a new ... work to detect the disease in its early stages. ... tongue, cheek, mouth, sinuses, throat and other areas in ... Institute’s Surveillance, Epidemiology, and Ends Results (SEER) program, 30 ...
(Date:7/30/2014)... 2014 Serial entrepreneur, Paul Mata, spent the ... However, like most people, in 2008 he suffered extreme financial ... better way, Paul carefully studied the difference between people who ... not. Based on the knowledge he acquired, he was able ... life and health, but also grow his clients' personal and ...
(Date:7/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... are more likely to develop dementia, but researchers have been ... the two. Specifically, they haven,t been able to figure ... depression help bring on dementia, or does dementia cause people ... 30 in the journal Neurology sheds more light ...
Breaking Medicine News(10 mins):Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3
... ... is happy to provide his patients with Invisalign clear aligners, a new technology that ... make getting straight teeth easier than ever before. , ... Torrance, California (PRWEB) April 29, 2010 -- ...
... cancers could soon allow researchers to identify groups of ... with angiogenesis-inhibitor drugs, a Spanish team reports. Dr ... reports new findings from an analysis of 135 lung ... Carlos Camps, evaluated the expression of 8 different genes ...
... (found in some foods) may help alleviate the severity ... new research study appearing in the May 2010 print ... ( http://www.jleukbio.org ), differing intestinal bacteria in celiac patients ... manipulating the intestinal microbiota with dietary strategies such as ...
... ... FDA Criticisms—Form 483 Letters—for Temperature, Humidity and other Controlled Environments” , ... (Vocus) April 29, ... Letters—for Temperature, Humidity and other Controlled Environments” is now available from Veriteq ...
... risky but can be beneficial, researchers say , THURSDAY, ... better if they undergo deep brain stimulation surgery in ... One year after having the procedure, patients who underwent ... ability to get around and engage in routine daily ...
... ... saying that seems to ring true according to husbands whose wives have had plastic surgery. ... a look at the transformative journey from the husband,s perspective. , ... Newport Beach, Calif (Vocus) April 29, 2010 -- Dr. ...
Cached Medicine News:Health News:Invisalign Clear Aligners Available at Blue Sky Family Dental by Torrance Dentist, Dr. Robert Mondavi 2Health News:Invisalign Clear Aligners Available at Blue Sky Family Dental by Torrance Dentist, Dr. Robert Mondavi 3Health News:Spanish gene expression data promise targeting of anti-angiogenesis treatment 2Health News:Gut bacteria offer new insights -- and hope -- for people with celiac disease 2Health News:Guide for US FDA-Regulated Organizations Now Available 2Health News:Guide for US FDA-Regulated Organizations Now Available 3Health News:Adding Surgery to Meds May Improve Life With Parkinson's 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 3Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: